ReviewViruses2023
Molecular Mechanisms of Antiviral Agents against Dengue Virus.
Review in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 2 syntheses or guidelines pooled it, 91 citations in OpenAlex.
- Effectiveness of antiviral, immunomodulatory and platelet-enhancing agents for treatment of dengue infection: A systematic review.Virulence · 2025Pooled it
- Deep Generative Models for the Discovery of Antiviral Peptides Targeting Dengue Virus: A Systematic Review.International journal of molecular sciences · 2025Pooled it
- High-Throughput Virtual Screening of Phytochemicals From Indian Medicinal Plants for the Identification of Potential Inhibitors Against NS2B-NS3 Protease of Dengue Virus.Biotechnology and applied biochemistry · 2026Article
- Precision repurposing of clinically characterized molecules targeting dengue virus RNA-dependent RNA polymerase: an in silico identification and in vitro validation.Folia microbiologica · 2026Article
- Dengue Virus NS5 Target Discovery: A Comprehensive in Silico Exploration of Novel Druggable Sites for Pan-Serotype Antiviral Design.International journal of molecular sciences · 2026Article
- Transcriptome signature for host directed antiviral reprogramming by Nimba & Triphala in macrophage Dengue virus infection models.Scientific reports · 2026Article
- Dataset of manually curated peptides against arthropod-borne viruses.Data in brief · 2026Article
- Drug repurposing against viral infections (2020-2025): clinical trials, computational strategies, and therapeutic interventions.Inflammopharmacology · 2026Review
- Efficacy of phytochemicals derived from Artocarpus heterophyllus (Jackfruit) as inhibitors against NS2B/NS3 protease of dengue virus: an in-silico investigation.Scientific reports · 2026Article
- Emergence of Two New Lineages of the Cosmopolitan Dengue Virus Serotype 2 in Yunnan, China, 2024.The Journal of infectious diseases · 2026Article
- Antiviral Strategies Against Dengue Virus: Recent Insights into Compounds Targeting Viral and Host Factors.Current topics in microbiology and immunology · 2026Review
- Diagnostic challenges in COVID 19 and dengue co-infection: a case series report from tertiary care centers of Saudi Arabia.Frontiers in medicine · 2026Article
- Engineered Nanobodies for early and accurate diagnosis of dengue virus infection.PLoS neglected tropical diseases · 2025Article
- Interplay between innate immune cells and inflammatory mediators in dengue infection: an evolving therapeutic paradigm.Expert reviews in molecular medicine · 2025Review
- Exploiting host kinases to combat dengue virus infection and disease.Antiviral research · 2025Review
- Phytochemicals of Different Medicinal Herbs as Potential Inhibitors Against Dengue Serotype 2 Virus: A Computational Approach.Molecular biotechnology · 2025Article
- Dengue virus: structure, genome, evolution and challenges to control and prevent transmission.Antonie van Leeuwenhoek · 2025Review
- Prolonged dengue viremia with predominantly ocular manifestations in a lung transplant recipient.BMC infectious diseases · 2025Article
- Antimicrobial Peptides Against Arboviruses: Mechanisms, Challenges, and Future Directions.Probiotics and antimicrobial proteins · 2025Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue is a major global health threat causing 390 million dengue infections and 25,000 deaths annually. The lack of efficacy of the licensed Dengvaxia vaccine and the absence of a clinically approved antiviral against dengue virus (DENV) drive the urgent demand for the development of novel anti-DENV therapeutics. Various antiviral agents have been developed and investigated for their anti-DENV activities. This review discusses the mechanisms of action employed by various antiviral agents against DENV. The development of host-directed antivirals targeting host receptors and direct-acting antivirals targeting DENV structural and non-structural proteins are reviewed. In addition, the development of antivirals that target different stages during post-infection such as viral replication, viral maturation, and viral assembly are reviewed. Antiviral agents designed based on these molecular mechanisms of action could lead to the discovery and development of novel anti-DENV therapeutics for the treatment of dengue infections. Evaluations of combinations of antiviral drugs with different mechanisms of action could also lead to the development of synergistic drug combinations for the treatment of dengue at any stage of the infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.